AI Pharmacogenomics (PGx) Platform

Pharmacogenomics, or PGx, studies how a person’s genes affect their response to drugs, informing the right medication and dose for that individual. An AI pharmacogenomics platform is the software that makes PGx usable in practice. It starts by interpreting genetic test results, translating raw genotype into phenotype, such as whether a patient is a poor, normal, or rapid metabolizer of a given drug pathway. It then applies curated drug-gene knowledge, grounded in evidence-based sources such as CPIC guidelines and FDA pharmacogenomic labeling, to determine what that phenotype means for specific medications. Crucially, it delivers this as clinical decision support within prescribing workflows, so a relevant drug-gene consideration surfaces when a clinician prescribes, rather than being buried in a report. PGx can be reactive, checked when a drug is considered, or preemptive, with results on file for future prescribing. Because PGx sits within genomic care, it connects to precision medicine and, for patient understanding, to genetic counseling. Throughout, the platform informs; the prescriber decides.

Taction Software delivers PGx platforms as a full engagement shaped to your setting, whether you are a health system, a pharmacy, a genetic testing lab, a precision medicine program, or a PGx company. We map your testing, prescribing workflows, and systems first, then build the modules that fit: PGx result ingestion, genotype-to-phenotype translation, curated drug-gene knowledge integration, clinical decision support in the EHR or e-prescribing workflow, reporting, and preemptive result storage. Because PGx guidance must be current and evidence-based, we integrate recognized knowledge sources and design to keep them updated. We deliver CDS that is specific, actionable, and well-timed, because poorly designed alerts cause alert fatigue and get ignored. We monitor the decision support, aligned with our healthcare AI observability practice. We handle genetic data with heightened protection throughout. Every module is composable, so you can start with translation and reporting and expand into full point-of-care CDS over time. The goal is a platform that makes PGx actionable and safe, delivering the right guidance at the right moment while the prescriber decides.

A well-designed PGx platform delivers value that unused PGx reports cannot, because the benefit of pharmacogenomics is realized only when results change prescribing appropriately. The clearest benefit is actionable guidance: translating genotype into clear, guideline-based recommendations at the point of prescribing helps clinicians choose medications and doses better suited to the individual. This can help avoid drugs unlikely to work or more likely to cause adverse reactions for a given patient, supporting safer, more effective prescribing. Point-of-care CDS ensures relevant PGx information appears when it matters, rather than being forgotten in a report. Preemptive PGx makes results reusable across future prescribing decisions. Evidence-based, current knowledge keeps guidance trustworthy. Well-designed alerts avoid the fatigue that makes clinicians ignore CDS. For programs, a strong platform turns PGx testing into realized clinical value rather than an unused expense. For patients, it can mean more personalized, safer medication decisions, always made by their clinician. Over time, integrated PGx becomes a standard part of thoughtful prescribing.

Taction Software follows a compliance-first, evidence-grounded process refined across more than a decade of healthcare delivery. We begin with discovery, documenting your testing, prescribing workflows, systems, and goals. We then design the architecture: result ingestion, genotype-to-phenotype translation, drug-gene knowledge integration, CDS delivery, and storage, with clinical accuracy and current evidence as guiding principles. Development runs in iterative sprints with clinical and pharmacy review, because PGx guidance must be clinically accurate and its alerts well-designed to be trusted. We integrate recognized knowledge sources and design update processes, since PGx evidence evolves. We pay careful attention to CDS design, making alerts specific, actionable, and appropriately timed to avoid fatigue. We validate translation and guidance accuracy, and we build the platform as decision support, with the prescriber always deciding. Because PGx involves genetic data, we apply heightened privacy and security. We then support deployment, monitoring, and ongoing knowledge updates. Throughout, we ground the platform in evidence and keep prescribing decisions human.

PGx platforms handle sensitive genetic data and deliver guidance that informs prescribing, so accuracy, evidence, security, and regulatory awareness are foundational. Taction Software builds on a HIPAA-aligned foundation, with encryption in transit and at rest, granular access controls, audit logging, and Business Associate Agreements where applicable, and heightened protection for genetic data. Our architecture integrates with EHR and e-prescribing systems using standards like HL7 and FHIR, including FHIR resources for genomics and CDS, so guidance appears in the prescribing workflow. We ground drug-gene guidance in recognized evidence sources such as CPIC guidelines and FDA pharmacogenomic labeling, and design update processes so guidance stays current. We validate genotype-to-phenotype translation and CDS accuracy, and design alerts to be specific and well-timed to avoid fatigue. Because software delivering drug-gene guidance may fall under clinical decision support or medical-device regulation depending on its design, we build with the appropriate pathway and oversight in mind, and recommend confirming it for the intended use. The prescriber always makes the prescribing decision.

Taction Software is a US-based healthcare software company founded in 2013, with offices in Chicago, Cheyenne, Austin, and Sacramento. We build healthcare software exclusively, so clinical workflow, integration, and compliance are part of our default process rather than afterthoughts. We have delivered more than 200 healthcare projects, including EHR and EMR platforms such as Voyant Health, FDA-registered mobile applications, and behavioral health tools. That clinical and integration depth matters in PGx, where accurate translation, current evidence, and well-designed point-of-care CDS determine whether the platform actually improves prescribing. We work as an evidence-grounded partner, building trustworthy, well-integrated decision support that respects prescriber judgment and regulatory reality. Our leadership brings deep, hands-on expertise, with our CEO contributing more than 20 years of personal experience in software and healthcare technology. Building with Taction means partnering with a team that has repeatedly taken healthcare software from concept to production in regulated settings.

PGx platform pricing depends on scope, integration, and knowledge and CDS complexity. Taction Software scopes each engagement to your setting, and typical ranges are as follows. A focused module or MVP, such as genotype-to-phenotype translation and reporting, generally falls between $40,000 and $80,000. A full PGx platform with knowledge integration, point-of-care CDS, EHR integration, and preemptive storage typically ranges from $80,000 to $200,000. Enterprise platforms with deep EHR integration, broad drug-gene coverage, and ongoing evidence maintenance start at $200,000 and up. Because clinical validation and evidence maintenance are essential, they are in scope, and any regulatory pathway work is scoped separately with appropriate expertise. Final pricing follows a discovery phase that defines workflows and integrations. We provide clear, itemized estimates so you can make PGx actionable in stages.